{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,26]],"date-time":"2026-06-26T23:35:52Z","timestamp":1782516952199,"version":"3.54.5"},"reference-count":22,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2023,3,1]],"date-time":"2023-03-01T00:00:00Z","timestamp":1677628800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,3,1]],"date-time":"2023-03-01T00:00:00Z","timestamp":1677628800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","eu-focus.europeanurology.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["European Urology Focus"],"published-print":{"date-parts":[[2023,3]]},"DOI":"10.1016\/j.euf.2022.09.007","type":"journal-article","created":{"date-parts":[[2022,9,24]],"date-time":"2022-09-24T02:34:12Z","timestamp":1663986852000},"page":"325-332","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":8,"title":["Long-term Recurrence and Progression Patterns in a Contemporary Series of Patients with Carcinoma In Situ of the Bladder With or Without Associated Ta\/T1 Disease Treated with Bacillus Calmette-Gu\u00e9rin: Implications for Risk-adapted Follow-up"],"prefix":"10.1016","volume":"9","author":[{"given":"Jos\u00e9 Daniel","family":"Subiela","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"\u00d3scar","family":"Rodr\u00edguez Faba","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J\u00falia","family":"Aumatell","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniel Antonio","family":"Gonzalez-Padilla","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Antonio","family":"Rosales Bordes","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jorge","family":"Huguet","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wojciech","family":"Krajewski","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ferran","family":"Algaba","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David","family":"L\u00f3pez Curtis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jennifer","family":"Brasero Burgos","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"\u00c1lvaro","family":"S\u00e1nchez Gonz\u00e1lez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Miguel \u00c1ngel","family":"Jim\u00e9nez Cidre","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Francisco Javier","family":"Burgos Revilla","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alberto","family":"Breda","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joan","family":"Palou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.euf.2022.09.007_b0005","doi-asserted-by":"crossref","first-page":"674","DOI":"10.1016\/j.euf.2019.03.012","article-title":"Carcinoma in situ of the urinary bladder: a systematic review of current knowledge regarding detection, treatment, and outcomes","volume":"6","author":"Subiela","year":"2020","journal-title":"Eur Urol Focus"},{"key":"10.1016\/j.euf.2022.09.007_b0010","doi-asserted-by":"crossref","first-page":"130","DOI":"10.1016\/S1078-1439(99)00020-4","article-title":"Updated concepts and treatment of carcinoma in situ","volume":"4","author":"Lamm","year":"1998","journal-title":"Urol Oncol"},{"key":"10.1016\/j.euf.2022.09.007_b0015","doi-asserted-by":"crossref","first-page":"144","DOI":"10.1159\/000049765","article-title":"Intravesical BCG in patients with carcinoma in situ of the urinary bladder: long-term results of EORTC GU Group phase II protocol 30861","volume":"40","author":"Jakse","year":"2001","journal-title":"Eur Urol"},{"key":"10.1016\/j.euf.2022.09.007_b0020","doi-asserted-by":"crossref","first-page":"1124","DOI":"10.1016\/S0022-5347(05)67707-5","article-title":"Maintenance bacillus Calmette-Guerin immunotherapy for recurrent TA, T1 and carcinoma in situ transitional cell carcinoma of the bladder: a randomized Southwest Oncology Group Study","volume":"163","author":"Lamm","year":"2000","journal-title":"J Urol"},{"key":"10.1016\/j.euf.2022.09.007_b0025","doi-asserted-by":"crossref","first-page":"258","DOI":"10.1016\/j.urolonc.2007.12.011","article-title":"The natural history of bladder carcinoma in situ after initial response to bacillus Calmette-Guerin immunotherapy","volume":"27","author":"Gofrit","year":"2009","journal-title":"Urol Oncol"},{"key":"10.1016\/j.euf.2022.09.007_b0030","doi-asserted-by":"crossref","first-page":"378","DOI":"10.1016\/j.eururo.2011.10.026","article-title":"A new and highly prognostic system to discern T1 bladder cancer substage","volume":"61","author":"van Rhijn","year":"2012","journal-title":"Eur Urol"},{"key":"10.1016\/j.euf.2022.09.007_b0035","doi-asserted-by":"crossref","first-page":"539","DOI":"10.1016\/j.acuro.2012.03.011","article-title":"A second transurethral resection could be not necessary in all high grade non-muscle-invasive bladder tumors","volume":"36","author":"Gaya","year":"2012","journal-title":"Actas Urol Esp"},{"key":"10.1016\/j.euf.2022.09.007_b0040","doi-asserted-by":"crossref","first-page":"225","DOI":"10.1038\/nrurol.2015.58","article-title":"Expert consensus document: consensus statement on best practice management regarding the use of intravesical immunotherapy with BCG for bladder cancer","volume":"12","author":"Kamat","year":"2015","journal-title":"Nat Rev Urol"},{"key":"10.1016\/j.euf.2022.09.007_b0045","doi-asserted-by":"crossref","first-page":"9e1","DOI":"10.1016\/j.urolonc.2021.05.006","article-title":"Impact of clinical and pathological subtypes of carcinoma in situ (CIS) of the bladder: lessons learned from long-term follow-up of a series of CIS patients treated with BCG","volume":"40","author":"Subiela","year":"2022","journal-title":"Urol Oncol"},{"key":"10.1016\/j.euf.2022.09.007_b0050","series-title":"BCG-unresponsive nonmuscle invasive bladder cancer: developing drugs and biologics for treatment guidance for industry","author":"US Food and Drug Administration","year":"2018"},{"key":"10.1016\/j.euf.2022.09.007_b0055","doi-asserted-by":"crossref","first-page":"1149","DOI":"10.1093\/aje\/kwj149","article-title":"Variable selection for propensity score models","volume":"163","author":"Brookhart","year":"2006","journal-title":"Am J Epidemiol"},{"key":"10.1016\/j.euf.2022.09.007_b0060","doi-asserted-by":"crossref","first-page":"237","DOI":"10.1007\/s00345-016-1856-9","article-title":"Is it possible to stop follow-up of patients with primary T1G3 urothelial carcinoma of the bladder managed with intravesical bacille Calmette-Guerin immunotherapy?","volume":"35","author":"Golabek","year":"2017","journal-title":"World J Urol"},{"key":"10.1016\/j.euf.2022.09.007_b0065","doi-asserted-by":"crossref","first-page":"503","DOI":"10.1016\/j.eururo.2011.11.011","article-title":"Should follow-up cystoscopy in bacillus Calmette-Guerin-treated patients continue after five tumour-free years?","volume":"61","author":"Holmang","year":"2012","journal-title":"Eur Urol"},{"key":"10.1016\/j.euf.2022.09.007_b0070","doi-asserted-by":"crossref","first-page":"227","DOI":"10.1016\/S0090-4295(01)01603-X","article-title":"Long-term follow-up of G3T1 transitional cell carcinoma of the bladder treated with intravesical bacille Calmette-Guerin: 18-year experience","volume":"59","author":"Pansadoro","year":"2002","journal-title":"Urology"},{"key":"10.1016\/j.euf.2022.09.007_b0075","doi-asserted-by":"crossref","first-page":"2131","DOI":"10.1007\/s00432-019-02956-6","article-title":"Prognosis of carcinoma in situ according to the presence of papillary bladder tumors after bacillus Calmette-Guerin immunotherapy","volume":"145","author":"Kim","year":"2019","journal-title":"J Cancer Res Clin Oncol"},{"key":"10.1016\/j.euf.2022.09.007_b0080","doi-asserted-by":"crossref","first-page":"1338","DOI":"10.21037\/tau.2020.03.40","article-title":"Clinical outcomes and survival differences between primary, secondary and concomitants carcinoma in situ of urinary bladder treated with BCG immunotherapy","volume":"9","author":"Piszczek","year":"2020","journal-title":"Transl Androl Urol"},{"key":"10.1016\/j.euf.2022.09.007_b0085","doi-asserted-by":"crossref","first-page":"133","DOI":"10.3233\/BLC-150016","article-title":"Development of systemic and topical drugs to treat non-muscle invasive bladder cancer","volume":"1","author":"Jarow","year":"2015","journal-title":"Bladder Cancer"},{"key":"10.1016\/j.euf.2022.09.007_b0090","doi-asserted-by":"crossref","first-page":"1612","DOI":"10.1097\/JU.0000000000001633","article-title":"Contemporary outcomes of patients with nonmuscle-invasive bladder cancer treated with bacillus Calmette-Guerin: implications for clinical trial design","volume":"205","author":"Matulay","year":"2021","journal-title":"J Urol"},{"key":"10.1016\/j.euf.2022.09.007_b0095","doi-asserted-by":"crossref","first-page":"306.e9","DOI":"10.1016\/j.urolonc.2018.02.009","article-title":"Upper tract urothelial carcinoma following intravesical bacillus Calmette-Guerin therapy for nonmuscle-invasive bladder cancer: results from a multi-institutional retrospective study","volume":"36","author":"Nishiyama","year":"2018","journal-title":"Urol Oncol"},{"key":"10.1016\/j.euf.2022.09.007_b0100","doi-asserted-by":"crossref","first-page":"1766","DOI":"10.3390\/biomedicines9121766","article-title":"Intravesical high dose BCG Tokyo and low dose BCG Tokyo with GMCSF+IFN\u03b1 induce systemic immunity in a murine orthotopic bladder cancer model","volume":"9","author":"Tham","year":"2021","journal-title":"Biomedicines"},{"key":"10.1016\/j.euf.2022.09.007_b0105","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1016\/j.eururo.2021.08.010","article-title":"European Association of Urology guidelines on non-muscle-invasive bladder cancer (Ta, T1, and carcinoma in situ)","volume":"81","author":"Babjuk","year":"2022","journal-title":"Eur Urol"},{"key":"10.1016\/j.euf.2022.09.007_b0110","doi-asserted-by":"crossref","first-page":"1021","DOI":"10.1016\/j.juro.2016.06.049","article-title":"Diagnosis and treatment of non-muscle invasive bladder cancer: AUA\/SUO guideline","volume":"196","author":"Chang","year":"2016","journal-title":"J Urol"}],"container-title":["European Urology Focus"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2405456922002085?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2405456922002085?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,11,7]],"date-time":"2025-11-07T06:54:39Z","timestamp":1762498479000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2405456922002085"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,3]]},"references-count":22,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2023,3]]}},"alternative-id":["S2405456922002085"],"URL":"https:\/\/doi.org\/10.1016\/j.euf.2022.09.007","relation":{},"ISSN":["2405-4569"],"issn-type":[{"value":"2405-4569","type":"print"}],"subject":[],"published":{"date-parts":[[2023,3]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Long-term Recurrence and Progression Patterns in a Contemporary Series of Patients with Carcinoma In Situ of the Bladder With or Without Associated Ta\/T1 Disease Treated with Bacillus Calmette-Gu\u00e9rin: Implications for Risk-adapted Follow-up","name":"articletitle","label":"Article Title"},{"value":"European Urology Focus","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.euf.2022.09.007","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2022 European Association of Urology. Published by Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}]}}